Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1b/2 Trial of AMG 655 in Combination with Panitumumab in Subjects with Metastatic Colorectal Cancer
2007-004722-25Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of conatumumab and panitumumab in colorectal cancer (CRC), sponsored by Amgen. Primary endpoint: Dose-limiting toxicity (DLT) incidence in Part 1. Started Dec 2007; status: completed.
02
Drugs
conatumumabpanitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-004722-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004722-25.